Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

VIVS vs CLYM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CLYM Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–0 Matrix Metrics)

CLYM Overall Winner 6-Pillar Tally: VIVS 2 – 3 CLYM (1 Tie) Matrix Metrics: VIVS 0 – 7 CLYM

As of Nov 19, 2026, Climb Bio, Inc. (CLYM) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). VIVS carries a Unified Composite Score of 36.8/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin), whereas CLYM carries 50.0/100 (HOLD) at $9.28 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: VIVS is currently in a Breakdown options structure phase (RSI 75.1); meanwhile CLYM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VIVS vs CLYM
VIVS NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap $2.4M
TTM Revenue $112,000
Forward P/E N/M
Beta / 30D Vol 0.83β · 480% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 5.0 Fund 38.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 75
RSI-14: 75.1 · SMA20: $0.15 · SMA50: $0.18
CLYM NASDAQ Head-to-Head Winner
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.28
-0.22% 1D
Market Cap $546.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.49β · 106% Vol
Unified Composite Score
50.0 / 100 HOLD
Tech 60.0 Fund 51.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.2%), weak momentum, RSI 41
RSI-14: 41.2 · SMA20: $10.09 · SMA50: $11.12

6-Pillar Scorecard Institutional Category Breakdown (VIVS 2 – 3 CLYM)

Columns: Metric · VIVS · CLYM
1. Valuation Multiples VIVS
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 9.6x N/M
2. Growth & Scale CLYM
Revenue Growth (YoY) -51.4% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $112,000 N/A
Market Cap $2.4M $546.3M
3. Profitability & Quality CLYM
Gross Margin N/A N/A
Operating Margin -10117.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -343.1% -29.3%
4. Balance Sheet & Cash Flow VIVS
Cash Generation (TTM) -$11M EBITDA N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.4M Net Cash $3.95 Book/Sh · -29.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CLYM
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VIVS (0) vs CLYM (7)
Institutional Metric VIVS CLYM Criterion Row Edge
Market Capitalization
Scale
$2.4M $546.3M Larger Scale CLYM
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-51.4% +0.0% Higher Growth CLYM
Operating Margin (TTM)
Profitability
-10117.0% 0.0% Higher Margin CLYM
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-343.1% -29.3% Higher ROE CLYM
52-Week Range Position
Momentum
5% ($0–$3) 46% ($2–$18) Stronger Trend CLYM
Beta / 30D Volatility
Risk Regime
0.83β · 480% Vol 1.49β · 106% Vol Lower Realized Risk CLYM
Unified Institutional Score
Composite Signal
36.8 / 100 (SELL) 50.0 / 100 (HOLD) Higher Composite CLYM
Trailing 12M Revenue (USD)
Operating Scale
$112,000 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 9.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$11M EBITDA ($1.4M Net Cash) N/A ($3.95 Book/Sh · -29.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VIVS +79.32 pp
VIVS: +64.69% · CLYM: -14.63%
3M Horizon VIVS +48.22 pp
VIVS: +1.92% · CLYM: -46.3%
6M Horizon CLYM +63.31 pp
VIVS: -78.25% · CLYM: -14.94%
1Y Horizon CLYM +472.85 pp
VIVS: -86.99% · CLYM: +385.86%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VIVS vs CLYM. Trailing 12-month operating profitability (VIVS -10117.0% vs CLYM 0.0%) and valuation multiples (VIVS N/M vs CLYM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

VIVS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$112,000
Gross MarginN/A
Op. Margin-10117.0%
ROE / Fwd P/E-343.1% · N/M
CLYM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-29.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VIVS BREAKDOWN
73d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact VIVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CLYM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CLYM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VIVS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.4M market capitalization and -10117.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CLYM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $546.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VIVS vs CLYM Key Questions & Quantitative Answers

As of Nov 19, 2026, Climb Bio, Inc. (CLYM) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). VIVS carries a Unified Composite Score of 36.8/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin), whereas CLYM carries 50.0/100 (HOLD) at $9.28 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: VIVS is currently in a Breakdown options structure phase (RSI 75.1); meanwhile CLYM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CLYM leads the Growth & Scale pillar: VIVS posts -51.4% YoY revenue growth and +0.0% YoY earnings growth on $112,000 TTM revenue (N/A gross margin, -10117.0% operating margin), compared with CLYM at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, VIVS generates $112,000 in USD-normalized revenue versus N/A for CLYM. In operating R&D and SG&A reinvestment, VIVS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CLYM.

VIVS screens cheaper on headline valuation multiples. VIVS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin), whereas CLYM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VIVS (-343.1% ROE) versus CLYM (-29.3% ROE) capital efficiency.

In options market volatility and institutional positioning, VIVS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.83β · 480% Vol realized risk). By comparison, CLYM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.49β · 106% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.